OCT 15, 2026 · JOURNAL ARTICLE
Impact of Metabolic Syndrome, Type 2 Diabetes Mellitus, and Metabolic Pharmacotherapies on the Progression of MASLD/MASH to Advanced Fibrosis and Cirrhosis: A Systematic Review
Archives of Gastroenterology Research
Background: Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction–Associated Steatohepatitis (MASH) are closely linked to obesity, insulin resi